SEC Filing Analysis: Amphastar Pharmaceuticals, Inc. (AMPH)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director at Amphastar Pharmaceuticals has filed a notice of intent to sell 500 shares of common stock, valued at approximately $12,650. The transaction is of low significance due to its negligible size relative to the company's market capitalization and the insider's established pattern of similar small sales.
• Market Impact: Neutral. The proposed sale is too small to have any meaningful impact on the stock price or trading volume.

Company Information

Field	Value
Company	Amphastar Pharmaceuticals, Inc.
Ticker Symbol	AMPH
CIK	0001297184
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Petersen Floyd F.
CIK	0001611286
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	144 (Notice of Proposed Sale)
Transaction Date	2025-11-03 (Approximate)
Transaction Code	N/A (Proposed Sale)
Security Type	Common Stock
Shares Involved	500
Price Per Share	~$25.30
Total Value	$12,650
Shares Owned After	Not specified
Ownership Type	Not specified

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$12,650
% of Market Cap	0.001%
Shares Transacted	500
% of Shares Outstanding	0.001%
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market capitalization of $1.19 billion, this $12,650 transaction is financially immaterial to the company.
• Transaction Significance: The sale represents a negligible fraction of both the company's market value and total shares outstanding, falling far below any threshold for significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction is de minimis and part of a disclosed trading plan. It does not signal any change in the insider's outlook on the company.

Volume & Sentiment

• Expected Volume Impact: None. The number of shares is too small to affect trading volume.
• Sentiment Indicator: Neutral. This is a routine, non-noteworthy transaction.

Additional Context

Transaction Notes

• Special Circumstances: The sale is being made pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024. This indicates the sale was pre-scheduled and not based on recent material non-public information.
• Transaction Pattern: The filing discloses a pattern of similar small sales by the insider over the past three months (500 shares sold in July, September, and October 2025), reinforcing the routine nature of this activity, likely for personal financial management.